Report cover image

Idiopathic Pulmonary Fibrosis Treatment Market: Global Market Size, Forecast, Insights, and Competitive Landscape

Publisher Prodture
Published Nov 02, 2024
Length 128 Pages
SKU # PROD19315081

Description

Idiopathic Pulmonary Fibrosis Treatment Market: Global Market Size, Forecast, Insights, and Competitive Landscape


The global idiopathic pulmonary fibrosis treatment market is expected to grow at a CAGR of around 8.2% during 2025-2034. This report on global idiopathic pulmonary fibrosis treatment market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. The report presents a clear picture of the global idiopathic pulmonary fibrosis treatment market by segmenting the market based on drug class, end-user, and region. Also, detailed profiles of companies operating in the idiopathic pulmonary fibrosis treatment market are provided in this report. We believe that this report will aid the professionals and industry stakeholders in making informed decision.

Market Drivers

• Increasing Prevalence of Fibrotic Diseases
• Rising Geriatric Population

Market Challenges

• Lack of Awareness
• Availability of Proper Treatment

Historical & Forecast Period

Base Year: 2024
Historical Period: 2020-2024
Forecast Period: 2025-2034

Market by Drug Class

• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors

Market by End User

• Hospitals
• Long-term Care Facilities
• Others

Market by Region

• Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherlands
Rest of Europe
• North America
United States
Canada
• Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Rest of Asia Pacific
• Latin America
Mexico
Brazil
Argentina
Rest of Latin America
• Middle East & Africa
Saudi Arabia
Turkey
Iran
United Arab Emirates
Rest of Middle East & Africa

Table of Contents

128 Pages
1. Preface
1.1 Objective
1.2 Target Audience & Key Offerings
1.3 Report’s Scope
1.4 Research Methodology
1.4.1 Phase I
1.4.2 Phase II
1.4.3 Phase III
1.5 Assumptions
2. Key Insights
3. Global Idiopathic Pulmonary Fibrosis Treatment Market
3.1. Introduction
3.2. Market Drives
3.3. Market Challenges
4. Global Idiopathic Pulmonary Fibrosis Treatment Market Analysis
4.1. Market Portraiture
4.2. Market Size
4.3. Market Forecast
4.4. Impact of COVID-19
5. Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class
5.1. Introduction
5.2. MAPK Inhibitors
5.3. Tyrosine Inhibitors
5.4. Autotaxin Inhibitors
6. Global Idiopathic Pulmonary Fibrosis Treatment Market by End User
6.1. Introduction
6.2. Hospitals
6.3. Long-term Care Facilities
6.4. Others
7. Global Idiopathic Pulmonary Fibrosis Treatment Market by Region
7.1. Introduction
7.2. Europe
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Russia
7.2.7. Netherlands
7.2.8. Rest of the Europe
7.3. North America
7.3.1. United States
7.3.2. Canada
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. South Korea
7.4.5. Australia
7.4.6. Indonesia
7.4.7. Rest of the Asia Pacific
7.5. Latin America
7.5.1. Mexico
7.5.2. Brazil
7.5.3. Argentina
7.5.4. Rest of Latin America
7.6. Middle East & Africa
7.6.1. Saudi Arabia
7.6.2. Turkey
7.6.3. Iran
7.6.4. United Arab Emirates
7.6.5. Rest of Middle East & Africa
8. SWOT Analysis
9. Porter’s Five Forces
10. Market Value Chain Analysis
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Company Profiles
11.2.1. AdAlta Pty Ltd.
11.2.2. Angion Biomedica Corp.
11.2.3. Boehringer Ingelheim International GmbH
11.2.4. Bristol-Myers Squibb Company
11.2.5. Cipla Inc.
11.2.6. F. Hoffmann-La Roche AG (Roche Holding AG)
11.2.7. Fibrogen Inc.
11.2.8. Galapagos NV
11.2.9. Liminal BioSciences Inc.
11.2.10. Medicinova Inc.
11.2.11. Merck & Co. Inc.
11.2.12. Novartis AG
11.2.13. Vectura Group Plc.
List of Figures
Figure 1: Global Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 2: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class, 2024
Figure 3: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User, 2024
Figure 4: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region, 2024
Figure 5: Global Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 6: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class (in %), 2024 & 2034
Figure 7: Global MAPK Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 8: Global MAPK Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 9: Global Tyrosine Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 10: Global Tyrosine Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 11: Global Autotaxin Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 12: Global Autotaxin Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 13: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User (in %), 2024 & 2034
Figure 14: Global Hospitals Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 15: Global Hospitals Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 16: Global Long-term Care Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 17: Global Long-term Care Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 18: Global Other Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 19: Global Other Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 20: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region (in %), 2024 & 2034
Figure 21: Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 22: Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 23: Europe Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2024 & 2034
Figure 24: Germany Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 25: United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 26: France Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 27: Italy Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 28: Spain Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 29: Russia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 30: Netherlands Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 31: Rest of Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 32: North America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 33: North America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 34: North America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2024 & 2034
Figure 35: United States Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 36: Canada Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 37: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 38: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 39: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2024 & 2034
Figure 40: China Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 41: Japan Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 42: India Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 43: South Korea Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 44: Australia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 45: Indonesia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 46: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 47: Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 48: Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 49: Latin America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2024 & 2034
Figure 50: Mexico Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 51: Brazil Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 52: Argentina Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 53: Rest of Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 54: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2024
Figure 55: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2025-2034
Figure 56: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2024 & 2034
Figure 57: Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 58: Turkey Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 59: Iran Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 60: UAE Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 61: Rest of Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2020-2034
Figure 62: Market Value Chain
List of Tables
Table 1: Global Idiopathic Pulmonary Fibrosis Treatment Market Portraiture
Table 2: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class (in US$ Million), 2024 & 2034
Table 3: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User (in US$ Million), 2024 & 2034
Table 4: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region (in US$ Million), 2024 & 2034
Table 5: Europe Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2024 & 2034
Table 6: North America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2024 & 2034
Table 7: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2024 & 2034
Table 8: Latin America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2024 & 2034
Table 9: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2024 & 2034
Table 10: List of Key Players

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us